Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.2K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

284
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
284
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

248
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
248

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced fatty acid availability rewires fibroblasts metabolism and decreases collagen deposition in lung fibrosis.

Cellular and molecular life sciences : CMLS·2026
Same author

Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5.

Journal of lipid research·2026
Same author

Blood-flow restriction resistance training improves skeletal muscle mitochondrial capacity and cardiovascular risk factors in type 2 diabetes.

Cell metabolism·2026
Same author

Blueberries Reduce Palm Oil-Induced Metabolic Endotoxemia in an In Vitro Human Intestinal-Immune Cell Model.

Molecular nutrition & food research·2025
Same author

Target Populations for Novel Triglyceride-Lowering Therapies.

Journal of the American College of Cardiology·2025
Same author

Regulation of Adipose Tissue Metabolism During Fasting.

Annual review of nutrition·2025

Related Experiment Video

Updated: Oct 18, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K

ANGPTL3 as therapeutic target.

Sander Kersten1

  • 1Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, the Netherlands.

Current Opinion in Lipidology
|September 28, 2021
PubMed
Summary

Inactivating ANGPTL3, a key factor in lipid metabolism, effectively lowers LDL-C and triglycerides. This offers a promising new approach for managing atherosclerotic cardiovascular disease risk.

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiology

Background:

  • Elevated LDL-C and triglycerides are significant risk factors for atherosclerotic cardiovascular disease.
  • Current lipid-lowering therapies often fail to achieve target levels for many patients.
  • ANGPTL3 has emerged as a novel therapeutic target for managing dyslipidemia.

Purpose of the Study:

  • To provide an overview of recent literature on ANGPTL3.
  • To focus on the therapeutic benefits of ANGPTL3 inactivation.
  • To discuss potential mechanisms of ANGPTL3's lipid-lowering effects.

Main Methods:

  • Review of recent literature on ANGPTL3.
  • Focus on therapeutic benefits of ANGPTL3 inactivation via monoclonal antibodies and antisense oligonucleotides.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

509

Related Experiment Videos

Last Updated: Oct 18, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

509
  • Discussion of emerging therapeutic approaches targeting ANGPTL3.

    • Main Results:

    • ANGPTL3, secreted by the liver, inhibits lipases by complexing with ANGPTL8.
    • Loss-of-function variants in ANGPTL3 are associated with lower LDL-C, triglycerides, and reduced cardiovascular risk.
    • Clinical studies show ANGPTL3 inactivation significantly lowers LDL-C and triglycerides in dyslipidemia patients.

    Conclusions:

    • Anti-ANGPTL3 therapies demonstrate significant potential for reducing LDL-C and triglycerides.
    • These therapies are promising for selected patient groups with dyslipidemia.
    • Targeting ANGPTL3 represents a novel strategy in cardiovascular disease prevention.